Moligo Technologies, founded in 2019 by scientists from Karolinska Institutet and based in Solna, Sweden, specializes in the enzymatic production of long, ultrapure single-stranded DNA (ssDNA) for applications in gene editing and gene therapies. Their proprietary technology enables the synthesis of ssDNA sequences up to 10 kilobases in length with fidelity exceeding 99.9999%, achieving industrial-scale production without compromising purity. Moligo aims to advance gene technologies by enhancing their safety, efficacy, and accessibility.